The use of all-trans retinoic acid (RA) for remission induction markedly increases survival of patients with acute promyelocytic leukemia (APL) compared to patients treated solely with cytotoxic chemotherapy. However, clinical resistance to this agent develops rapidly, which has been associated with a progressive decline in plasma drug concentrations. Previous studies suggested that 9-cis RA, a retinoid receptor 'pan agonist' did not induce its own catabolism to the same extent as alltrans RA. Therefore, we conducted a dose-ranging study of this compound in patients with both relapsed and newly diagnosed APL. We treated 18 patients with morphologically diagnosed APL (13 relapsed, five newly diagnosed). The daily dose of 9-cis RA ranged from 30 to 230 mg/m 2 /day given as a single oral dose. Four of 12 (33%) relapsed patients (three of whom were previously treated with all-trans RA) and four of five (80%) newly diagnosed patients achieved complete remission. The sole failure in the newly diagnosed group died early from an intracranial hemorrhage. One other patient with t(9;12) translocation had substantial hematologic improvement. The drug was generally well tolerated; headache and dry skin were the most common adverse reactions. Three patients were treated with corticosteroids for signs of incipient 'RA syndrome.' These preliminary data suggest that 9-cis RA is an effective agent for remission induction and deserves further investigation in patients with retinoid-sensitive APL.
Introduction
Acute promyelocytic leukemia (APL) is characterized by reciprocal translocations between chromosomes 15 and 17 that fuse genes encoding PML and a nuclear retinoic acid receptor (RAR-␣). 1, 2 The resulting fusion gene, PML/RAR-␣, encodes a chimeric protein that blocks normal myeloid differentiation. 3 The use of all-trans RA for remission induction of APL, followed by consolidation with several cycles of cytotoxic chemotherapy, has increased survival almost three-fold compared to patients treated with chemotherapy alone. [4] [5] [6] [7] [8] [9] A major limitation of all-trans RA therapy is the development of retinoid resistance, 5, 10 which is manifested clinically by a limited duration of remission in patients treated with all-trans RA alone, who are then clinically unresponsive to further retinoid exposure. Patients on continuous all-trans RA therapy manifest a progressive decline in plasma drug levels, 10, 11 and this observation has engendered speculation that acquired retinoid resistance was related to autoinduced catabolism of the drug. [10] [11] [12] [13] In 1990, the family of retinoid 'X' receptors (RXRs) was described, which were shown to act as cofactors for RARs as well as receptors for vitamin D, thyroid hormone and peroxi- some proliferation-associated proteins.
14-17 Whereas all-trans RA binds only RARs, 9-cis RA binds and activates both RARs and RXRs. [18] [19] [20] Preclinical studies also showed that 9-cis RA was more potent than all-trans RA in inducing myeloid differentiation in HL60 cells. 21, 22 In a preliminary report, we found that 9-cis RA could induce complete remission in APL, but the drug did not appear capable of reversing clinically acquired retinoid resistance. 23 In this final report, we show non-comparative data that suggests 9-cis RA can induce remission in both previously treated and newly diagnosed patients at a level that appears at least equivalent to that of all-trans RA.
Materials and methods

Study design
Both newly diagnosed and relapsed patients with APL were eligible for entry into this dose-ranging study. 9-cis RA (supplied as ALRT1057; LGD1057: Panretin) was supplied in soft gelatin capsules containing either 10 or 25 mg of drug (Ligand Pharmaceuticals, San Diego, CA, USA). The lowest daily dose was 30 mg/m 2 , which was given as a single daily oral dose until clinical response, or failure (eg rising blast count in peripheral blood or bone marrow, etc) was determined. In patients who achieved complete remission (CR), therapy was continued for approximately 30 days after the date of CR. Dose escalation in the same patient was not performed. This study was conducted in parallel with a phase 1 study in patients with non-hematological neoplasms, 24 which in part determined the dose that could be concurrently used in APL patients. Once a relatively high effective dose for remission induction was identified (230 mg/m 2 ), doses in subsequent relapsed patients were progressively de-escalated in an effort to establish the lowest effective dose. Newly diagnosed patients were enrolled at doses that had been determined effective for remission induction in relapsed patients.
Newly diagnosed patients who achieved CR received additional therapy as consolidation, which generally consisted of three cycles of idarubicin and cytosine arabinoside. The first cycle was equivalent to a full-dose induction course (ie idarubicin 12 mg/m 2 /day for 3 days, plus cytosine arabinoside 200 mg/m 2 /day for 5 days). The subsequent two courses used idarubicin 12 mg/m 2 /day for 2 days and cytosine arabinoside 100 mg/m 2 /day for 5 days after recovery from the preceding cycle. Selected patients also received therapy with a recombinant humanized monoclonal antibody directed against CD33 (rHuM195). 25 Patients who were treated after relapsing from prior therapy and who achieved CR with 9-cis RA received a variety of post-remission therapies.
During the study, patients were monitored with periodic determinations of complete blood counts, serum biochemical analyses, and bone marrow aspirates and/or biopsies. The clinical protocol was reviewed and approved in advance by this center's Institutional Review Board. Signed informed consent was obtained from all patients.
Results
Patient characteristics
Between February 1994 and July 1996, 18 patients were enrolled. Twelve patients with molecularly confirmed APL had been previously treated with chemotherapy and 11 of these 12 patients had received prior all-trans RA. One of these patients had relapsed from an allogeneic T cell-depleted bone marrow transplant, and one patient had previously received a monoclonal antibody in addition to all-trans RA and cytotoxic chemotherapy. Five patients were treated at the time of their initial diagnosis. Relevant characteristics of this patient group are presented in Table 1 . The diagnosis of APL was confirmed in 17 of 18 patients by cytogenetics or RT-PCR for PML/RAR-␣. Despite morphological characteristics that were typical of APL, one patient had a variant (9;12) translocation (see below).
Clinical efficacy
Four of the 12 (33%) previously treated confirmed APL patients (three of the four CR patients had previously received all-trans RA) and four of the five (80%) newly diagnosed patients achieved complete remission. The median time to CR was 51 days (range, 23-61 days). Doses that were effective in inducing complete remission ranged from 50 to 230 mg/m 2 ( Table 2 ). Seven of the eight patients who achieved CR were positive for PML/RAR-␣ by RT-PCR at the time of CR, whereas only one was negative. Seven of these patients received consolidation with a recombinant humanized anti-CD33 monoclonal antibody (rHuM195); the assay converted to negative in three of the seven patients after antibody therapy alone. Three of the newly diagnosed patients who achieved CR remain alive in first remission for durations ranging from 17+ to 27+ months. One newly diagnosed patient relapsed after a remission duration of 19.3 months. Subsequently, this patient failed remission induction with all-trans RA but ultimately achieved a second remission with cytotoxic chemotherapy. Three of the four relapsed patients who achieved CR had remission durations that have ranged from 14+ to 40+ months; one patient relapsed and died 9 months later. One of these three patients relapsed a second time after a remission duration of 29.6 months and was subsequently reinduced into a complete remission with arsenic trioxide. One child (18 month old female) with a 9;12 translocation was previously resistant to three cycles of chemotherapy and an abbreviated 17 day course of all-trans RA. Shortly after beginning 9-cis RA (140 mg/m 2 /day), she developed progressive leukocytosis and respiratory distress that ultimately required endotracheal intubation, mechanical ventilation and cessation of therapy. Her clinical condition was consistent with both 'retinoid acid syndrome' and Pneumocystis pneumonia, and she was treated with corticosteroids and trimethoprim/sulfamethoxazole. Upon recovery, she had attained marked improvement in both her total granulocyte and platelet counts (see Figure 1) ; however, further therapy was declined by her parents and she expired approximately 2 months later from progressive leukemia.
Adverse effects
9-cis RA was generally well tolerated ( Table 3 ). The most common adverse reactions were headache (76%) and dry skin (59%). Three patients were treated with high-dose corticosteroids for signs suggestive of incipient 'RA syndrome' (eg weight gain, hectic fever, etc). Four patients experienced bone pain that required narcotic analgesics. One patient developed hypercalcemia. Minor adverse effects included liver function abnormalities (ie increases in serum alkaline phosphatase and aspartate aminotransferase activity).
Discussion
The use of all-trans RA during remission induction has been a major advance in the treatment of APL. Since the introduction of all-trans RA in the early 1990s, several international groups have reported a marked increase in both disease-free and overall survival. [4] [5] [6] [7] [8] [9] 26 We recently reported a 5-year update of our experience, which showed approximately 2.5-fold increase in the proportion of patients alive 5 years from diagnosis compared with patients who were solely treated with chemotherapy. 9 However, therapy with all-trans RA has presented several new challenges including development of the 'RA syndrome' and the emergence of RA resistance in patients who relapse.
Previous studies have shown that continuous therapy with all-trans RA results in a progressive decline in plasma drug levels. [10] [11] [12] [13] Various mechanisms for this phenomenon have been postulated, including induction of cytochrome P450 oxidases, 12, 22 an increase in oxidative cofactors (especially lipid hydroperoxides), 17, 27 and an increased expression of cytoplasmic RA-binding proteins. 28 Inhibitors of P450 enzymes, such as ketoconazole or liarozole, transiently increase plasma levels of all-trans RA. 12, 13 However, these agents have not been reported as decreasing the incidence of clinical resistance nor overcoming clinically acquired retinoid resistance. Theoretically, this declining drug level could facilitate the emergence and eventual overgrowth of relatively resistant leukemic cells.
In a previous study, we 23, 24 and others 23, 24 found that 9-cis RA was associated with a somewhat different pattern of adverse reactions than all-trans RA. Mucous membrane effects, such as cheilitis, xeroderma or skin peeling, occurred in approximately 90% of patients treated in phase 1 trials of all-trans RA. [29] [30] [31] Conversely, these adverse reactions were observed in less than half of the patients in our study with 9-cis RA. However, hyperlipidemia (particularly hyper-
Figure 1
Response in peripheral blood leukocytes (left axis) and platelets (right axis) in a patient with acute promyelocytic leukemia characterized by a t(9;12) translocation during treatment with 9-cis retinoic acid. Despite the atypical translocation, the disease appeared retinoidresponsive, with induction of hyperleukocytosis and recovery from severe thrombocytopenia.
Table 2
Dose escalation schedule and response to 9-cis retinoic acid triglceridemia) and hypercalcemia was observed in 42 and 44% of patients, respectively, in the initial study of 9-cis RA from this center. 24 Relatively stable plasma levels of 9-cis have been maintained with chronic dosing up to 140 mg/m 2 , but that at higher doses, plasma AUCs have tended to decrease over time. 24, 30 The retinoid receptors bind their cognate ligands with varying affinity. For example, all-trans RA primarily binds RARs and has very low affinity for RXRs. By contrast, 9-cis RA binds both RARs and RXRs with high affinity, and this pan-receptor activation suggested that this ligand might exert unique biological activities. 9-cis RA appears to be at least as effective as all-trans RA for remission induction in patients with retinoidsensitive APL. Although this agent does not appear to overcome clinically acquired retinoid resistance, its more stable plasma concentrations at lower dose levels, which are clinically effective, suggest its possible utility as a maintenance therapy in APL.
This study confirms that 9-cis RA can induce complete remission in patients with retinoid-sensitive APL. Given the exploratory nature of this study, we could not reliably determine the comparative advantage of 9-cis vs all-trans RA. However, this new agent is clearly effective for remission induction in retinoid naive patients with a molecularly confirmed diagnosis of APL.
